Islet Cell Tumors of the Pancreas
- PMID: 26895682
- DOI: 10.1016/j.gtc.2015.10.007
Islet Cell Tumors of the Pancreas
Abstract
Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.
Keywords: Islet cell tumor; Pancreas; Pancreas cancer; Pancreatic neuroendocrine tumors (PNET); Targeted molecular therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Pancreatic neuroendocrine tumours.Best Pract Res Clin Gastroenterol. 2008;22(1):183-205. doi: 10.1016/j.bpg.2007.10.008. Best Pract Res Clin Gastroenterol. 2008. PMID: 18206821 Review.
-
Pancreatic neuroendocrine neoplasms.Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Minerva Gastroenterol Dietol. 2012. PMID: 23207615 Review.
-
Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.World J Gastroenterol. 2015 Aug 28;21(32):9512-25. doi: 10.3748/wjg.v21.i32.9512. World J Gastroenterol. 2015. PMID: 26327759 Free PMC article. Review.
-
Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.Am J Gastroenterol. 1998 Jan;93(1):66-70. doi: 10.1111/j.1572-0241.1998.066_c.x. Am J Gastroenterol. 1998. PMID: 9448177
-
Management of pancreatic neuroendocrine tumors.Surg Clin North Am. 2013 Jun;93(3):675-91. doi: 10.1016/j.suc.2013.02.001. Epub 2013 Apr 3. Surg Clin North Am. 2013. PMID: 23632152 Review.
Cited by
-
Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.Rev Endocr Metab Disord. 2018 Jun;19(2):179-192. doi: 10.1007/s11154-018-9465-0. Rev Endocr Metab Disord. 2018. PMID: 30293213 Review.
-
Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016.J Oncol. 2021 Dec 22;2021:4302675. doi: 10.1155/2021/4302675. eCollection 2021. J Oncol. 2021. PMID: 34976056 Free PMC article.
-
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients.J Pathol Transl Med. 2017 Jul;51(4):388-395. doi: 10.4132/jptm.2017.03.19. Epub 2017 Jun 8. J Pathol Transl Med. 2017. PMID: 28597868 Free PMC article.
-
Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.Virchows Arch. 2018 May;472(5):739-748. doi: 10.1007/s00428-018-2353-x. Epub 2018 Apr 18. Virchows Arch. 2018. PMID: 29666945
-
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23. Clin Cancer Res. 2017. PMID: 27663587 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical